BACKGROUND: Anti-tumour necrosis factor (TNF) therapy is now well established in the treatment of inflammatory bowel disease and the risk of opportunistic infection is recognized. However, specific considerations regarding screening, detection, prevention and treatment of chronic viral infections in the context of anti-TNF therapy in inflammatory bowel disease are not widely adopted in practice. AIM: To provide a detailed and comprehensive review of the relevance of chronic viral infections in the context of anti-TNF therapy in inflammatory bowel disease. METHODS: Literature search was conducted using Medline, Pubmed and Embase using the terms viral infection, hepatitis, herpes, CMV, EBV, HPV, anti-TNF, infliximab, adalimumab, certolizumab pegol and etanercept. Hepatitis B and C and HIV had the largest literature associated and these have been summarized in Tables. RESULTS: Particular risks are associated with the use of anti-TNF drugs in patients with hepatitis B infection, in whom reactivation is common unless anti-viral prophylaxis is used. Reactivation of herpes zoster is the most common viral problem associated with anti-TNF treatment, and may be particularly severe. Primary varicella infection may present with atypical features in patients on anti-TNF. CONCLUSION: Appreciation of risks of chronic viral disease associated with anti-TNF therapy may permit early recognition, prophylaxis and treatment.
BACKGROUND:Anti-tumour necrosis factor (TNF) therapy is now well established in the treatment of inflammatory bowel disease and the risk of opportunistic infection is recognized. However, specific considerations regarding screening, detection, prevention and treatment of chronic viral infections in the context of anti-TNF therapy in inflammatory bowel disease are not widely adopted in practice. AIM: To provide a detailed and comprehensive review of the relevance of chronic viral infections in the context of anti-TNF therapy in inflammatory bowel disease. METHODS: Literature search was conducted using Medline, Pubmed and Embase using the terms viral infection, hepatitis, herpes, CMV, EBV, HPV, anti-TNF, infliximab, adalimumab, certolizumab pegol and etanercept. Hepatitis B and C and HIV had the largest literature associated and these have been summarized in Tables. RESULTS: Particular risks are associated with the use of anti-TNF drugs in patients with hepatitis B infection, in whom reactivation is common unless anti-viral prophylaxis is used. Reactivation of herpes zoster is the most common viral problem associated with anti-TNF treatment, and may be particularly severe. Primary varicella infection may present with atypical features in patients on anti-TNF. CONCLUSION: Appreciation of risks of chronic viral disease associated with anti-TNF therapy may permit early recognition, prophylaxis and treatment.
Authors: Ako Takakura; Howard H Tessler; Debra A Goldstein; Yan Guex-Crosier; Chi-Chao Chan; Diane M Brown; Jennifer E Thorne; Robert Wang; Emmett T Cunningham Journal: Ocul Immunol Inflamm Date: 2014-03-21 Impact factor: 3.070
Authors: Gregor Ebert; Simon Preston; Cody Allison; James Cooney; Jesse G Toe; Michael D Stutz; Samar Ojaimi; Hamish W Scott; Nikola Baschuk; Ueli Nachbur; Joseph Torresi; Ruth Chin; Danielle Colledge; Xin Li; Nadia Warner; Peter Revill; Scott Bowden; John Silke; C Glenn Begley; Marc Pellegrini Journal: Proc Natl Acad Sci U S A Date: 2015-04-20 Impact factor: 11.205
Authors: Maria Ana Rafael; Luís Carvalho Lourenço; Ana Maria Oliveira; Teresa Branco; Carla Carneiro; Ana Costa; Jorge Reis Journal: Clin J Gastroenterol Date: 2019-05-20
Authors: Gregory A Yanik; Shin Mineishi; John E Levine; Carrie L Kitko; Eric S White; Mark T Vander Lugt; Andrew C Harris; Thomas Braun; Kenneth R Cooke Journal: Biol Blood Marrow Transplant Date: 2011-12-10 Impact factor: 5.742